Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 May 3;17(5):e255242.
doi: 10.1136/bcr-2023-255242.

Polymyxin B-induced Bartter syndrome

Affiliations
Case Reports

Polymyxin B-induced Bartter syndrome

Bhavesh Mohan Lal et al. BMJ Case Rep. .

Abstract

Bartter syndrome is a genetic disorder characterised by chloride-unresponsive metabolic alkalosis, hypokalaemia, hypomagnesaemia and hypercalciuria. While it commonly presents antenatally or in early infancy, sometimes, drugs can induce a state similar to Bartter syndrome in any age group, called acquired Bartter syndrome. Polymyxins and aminoglycosides are the most commonly implicated drugs. Polymyxin B and polymyxin E (popularly known as colistin) are the two chemically similar polymyxins that are commonly used clinically. While colistin is frequently associated with nephrotoxicity, polymyxin B is generally considered less nephrotoxic. This difference is due to the way these two drugs are handled by the kidneys. In this case report, we discuss a middle-aged male who developed Bartter syndrome due to polymyxin B, which resolved on discontinuation of the drug, and re-appeared after its re-introduction later. This case exemplifies the nephrotoxicity caused by polymyxin B and the need for vigilance when using this drug.

Keywords: Adult intensive care; Drugs: infectious diseases; Fluid electrolyte and acid-base disturbances; Unwanted effects / adverse reactions.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Konrad M, Nijenhuis T, Ariceta G, et al. . Diagnosis and management of bartter syndrome: executive summary of the consensus and recommendations from the European rare kidney disease reference network working group for tubular disorders. Kidney Int 2021;99:324–35. 10.1016/j.kint.2020.10.035 - DOI - PubMed
    1. Chou CL, Chen YH, Chau T, et al. . Acquired bartter-like syndrome associated with gentamicin administration. Am J Med Sci 2005;329:144–9. 10.1097/00000441-200503000-00007 - DOI - PubMed
    1. Tabish M, Mahendran M, Ray A, et al. . Colistin-induced acquired bartter-like syndrome: an unusual cause of meltdown. BMJ Case Rep 2020;13:e232630. 10.1136/bcr-2019-232630 - DOI - PMC - PubMed
    1. Sandal G, Akbay Ş, Ozen M. Acquired bartter-like syndrome association with netilmicin therapy in an extremely low birth weight infant. Ren Fail 2014;36:123–5. 10.3109/0886022X.2013.832861 - DOI - PubMed
    1. Kamal Eldin T, Tosone G, Capuano A, et al. . Reversible hypokalemia and bartter-like syndrome during prolonged systemic therapy with colistimethate sodium in an adult patient. Drug Saf Case Rep 2017;4:10. 10.1007/s40800-017-0052-1 - DOI - PMC - PubMed

Publication types

LinkOut - more resources